Show simple item record

Ruxolitinib versus best available therapy for PV intolerant or resistant to Hydroxycarbamide a randomised trial

dc.contributor.authorHarrison, C
dc.contributor.authorNangalia, J
dc.contributor.authorBoucher, R
dc.contributor.authorJackson, A
dc.contributor.authorYap, C
dc.contributor.authorO'Sullivan, J
dc.contributor.authorFox, S
dc.contributor.authorAilts, I
dc.contributor.authorDueck, A
dc.contributor.authorGeyer, H
dc.contributor.authorMesa, R
dc.contributor.authorDunn, W
dc.contributor.authorNadezhdin, E
dc.contributor.authorCurto-Garcia, N
dc.contributor.authorGreen, A
dc.contributor.authorWilkins, B
dc.contributor.authorCoppell, J
dc.contributor.authorLaurie, J
dc.contributor.authorGarg, M
dc.contributor.authorEwing, J
dc.contributor.authorKnapper, S
dc.contributor.authorCrowe, J
dc.contributor.authorChen, F
dc.contributor.authorKoutsavlis, I
dc.contributor.authorGodfrey, A
dc.contributor.authorArami, S
dc.contributor.authorDrummond, M
dc.contributor.authorByrne, J
dc.contributor.authorClark, F
dc.contributor.authorMead-Harvey, C
dc.contributor.authorBaxter, E
dc.contributor.authorMcMullin, MF
dc.contributor.authorMead, A
dc.coverage.spatialENGLAND, Birmingham
dc.date.accessioned2024-01-29T09:49:55Z
dc.date.available2024-01-29T09:49:55Z
dc.date.issued2023-04-01
dc.identifier.citationBritish Journal of Haematology, 2023, 201 pp. 88 - 88en_US
dc.identifier.issn0007-1048
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/6126
dc.identifier.eissn1365-2141
dc.identifier.eissn1365-2141
dc.format.extent88 - 88
dc.language.isoengen_US
dc.publisherWILEYen_US
dc.relation.ispartofBritish Journal of Haematology
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_US
dc.titleRuxolitinib versus best available therapy for PV intolerant or resistant to Hydroxycarbamide a randomised trialen_US
dc.typeConference Proceeding
dcterms.dateAccepted2023-03-21
dc.date.updated2024-01-25T10:28:21Z
rioxxterms.versionVoRen_US
rioxxterms.licenseref.startdate2023-04-01
rioxxterms.typeConference Paper/Proceeding/Abstracten_US
pubs.organisational-groupICR
pubs.organisational-groupICR/Primary Group
pubs.organisational-groupICR/Primary Group/ICR Divisions
pubs.organisational-groupICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-groupICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit
pubs.publication-statusPublished
pubs.volume201
icr.researchteamClin Trials & Stats Uniten_US
dc.contributor.icrauthorYap, Christina
icr.provenanceDeposited by Ms Jessica Perry (impersonating Prof Christina Yap) on 2024-01-25. Deposit type is initial. No. of files: 1. Files: harrison-et-al-2023-ruxolitinib-versus-best-available-therapy-for-polycythemia-vera-intolerant-or-resistant-to.pdf


Files in this item

Thumbnail
Name:
harrison-et-al-2023-ruxolitini ...
Size:
1004.Kb
Format:
PDF
View/Open

This item appears in the following collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/